# The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes

Study · id `cardio:ct-nct06750783` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06750783](<https://clinicaltrials.gov/study/NCT06750783>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06750783

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 398 participants.

## Technical summary

Registry record NCT06750783. Randomized; no masking; primary purpose treatment. Start 2024-12-31 (actual); primary completion 2026-03-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 398 participants (planned count; ClinicalTrials.gov record NCT06750783, source copy `cardio:ctgov-nct06750783-2025-04-03`, retrieved 2026-10-26)
- Started: 2024-12-31 (actual) (ClinicalTrials.gov record NCT06750783, source copy `cardio:ctgov-nct06750783-2025-04-03`, retrieved 2026-10-26)
- Primary completion: 2026-03-31 (anticipated) (ClinicalTrials.gov record NCT06750783, source copy `cardio:ctgov-nct06750783-2025-04-03`, retrieved 2026-10-26)
- Completion: 2026-03-31 (anticipated) (ClinicalTrials.gov record NCT06750783, source copy `cardio:ctgov-nct06750783-2025-04-03`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06750783, source copy `cardio:ctgov-nct06750783-2025-04-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06750783-2025-04-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes
- Acronym: Xuezhikang
- Condition: Prediabetic State (IGT)
- Intervention (Drug): Xuezhikang
- Intervention (Drug): Atorvastatin
- Lead sponsor: Beijing Tsinghua Chang Gung Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)

## Provenance

Content hash: f233d17d125da9f75416e0faa71e539ec8399c8d84aa2d51002b7946536b3004
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
